Cargando…
Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
[Image: see text] Histone deacetylase 11 (HDAC11) preferentially removes fatty acid residues from lysine side chains in a peptide or protein environment. Here, we report the development and validation of a continuous fluorescence-based activity assay using an internally quenched TNFα-derived peptide...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882135/ https://www.ncbi.nlm.nih.gov/pubmed/31788622 http://dx.doi.org/10.1021/acsomega.9b02808 |
_version_ | 1783474088555053056 |
---|---|
author | Kutil, Zsófia Mikešová, Jana Zessin, Matthes Meleshin, Marat Nováková, Zora Alquicer, Glenda Kozikowski, Alan Sippl, Wolfgang Bařinka, Cyril Schutkowski, Mike |
author_facet | Kutil, Zsófia Mikešová, Jana Zessin, Matthes Meleshin, Marat Nováková, Zora Alquicer, Glenda Kozikowski, Alan Sippl, Wolfgang Bařinka, Cyril Schutkowski, Mike |
author_sort | Kutil, Zsófia |
collection | PubMed |
description | [Image: see text] Histone deacetylase 11 (HDAC11) preferentially removes fatty acid residues from lysine side chains in a peptide or protein environment. Here, we report the development and validation of a continuous fluorescence-based activity assay using an internally quenched TNFα-derived peptide derivative as a substrate. The threonine residue in the +1 position was replaced by the quencher amino acid 3′-nitro-l-tyrosine and the fatty acyl moiety substituted by 2-aminobenzoylated 11-aminoundecanoic acid. The resulting peptide substrate enables fluorescence-based direct and continuous readout of HDAC11-mediated amide bond cleavage fully compatible with high-throughput screening formats. The Z′-factor is higher than 0.85 for the 15 μM substrate concentration, and the signal-to-noise ratio exceeds 150 for 384-well plates. In the absence of NAD(+), this substrate is specific for HDAC11. Reevaluation of inhibitory data using our novel assay revealed limited potency and selectivity of known HDAC inhibitors, including Elevenostat, a putative HDAC11-specific inhibitor. |
format | Online Article Text |
id | pubmed-6882135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-68821352019-11-29 Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors Kutil, Zsófia Mikešová, Jana Zessin, Matthes Meleshin, Marat Nováková, Zora Alquicer, Glenda Kozikowski, Alan Sippl, Wolfgang Bařinka, Cyril Schutkowski, Mike ACS Omega [Image: see text] Histone deacetylase 11 (HDAC11) preferentially removes fatty acid residues from lysine side chains in a peptide or protein environment. Here, we report the development and validation of a continuous fluorescence-based activity assay using an internally quenched TNFα-derived peptide derivative as a substrate. The threonine residue in the +1 position was replaced by the quencher amino acid 3′-nitro-l-tyrosine and the fatty acyl moiety substituted by 2-aminobenzoylated 11-aminoundecanoic acid. The resulting peptide substrate enables fluorescence-based direct and continuous readout of HDAC11-mediated amide bond cleavage fully compatible with high-throughput screening formats. The Z′-factor is higher than 0.85 for the 15 μM substrate concentration, and the signal-to-noise ratio exceeds 150 for 384-well plates. In the absence of NAD(+), this substrate is specific for HDAC11. Reevaluation of inhibitory data using our novel assay revealed limited potency and selectivity of known HDAC inhibitors, including Elevenostat, a putative HDAC11-specific inhibitor. American Chemical Society 2019-11-15 /pmc/articles/PMC6882135/ /pubmed/31788622 http://dx.doi.org/10.1021/acsomega.9b02808 Text en Copyright © 2019 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Kutil, Zsófia Mikešová, Jana Zessin, Matthes Meleshin, Marat Nováková, Zora Alquicer, Glenda Kozikowski, Alan Sippl, Wolfgang Bařinka, Cyril Schutkowski, Mike Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors |
title | Continuous Activity Assay for HDAC11 Enabling Reevaluation
of HDAC Inhibitors |
title_full | Continuous Activity Assay for HDAC11 Enabling Reevaluation
of HDAC Inhibitors |
title_fullStr | Continuous Activity Assay for HDAC11 Enabling Reevaluation
of HDAC Inhibitors |
title_full_unstemmed | Continuous Activity Assay for HDAC11 Enabling Reevaluation
of HDAC Inhibitors |
title_short | Continuous Activity Assay for HDAC11 Enabling Reevaluation
of HDAC Inhibitors |
title_sort | continuous activity assay for hdac11 enabling reevaluation
of hdac inhibitors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882135/ https://www.ncbi.nlm.nih.gov/pubmed/31788622 http://dx.doi.org/10.1021/acsomega.9b02808 |
work_keys_str_mv | AT kutilzsofia continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors AT mikesovajana continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors AT zessinmatthes continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors AT meleshinmarat continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors AT novakovazora continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors AT alquicerglenda continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors AT kozikowskialan continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors AT sipplwolfgang continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors AT barinkacyril continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors AT schutkowskimike continuousactivityassayforhdac11enablingreevaluationofhdacinhibitors |